HTA14 Expanding the HTA Cost-Effectiveness Analyses for CheckMate 9LA: Nivolumab Plus Ipilimumab Plus Chemotherapy As First-Line Strategy for Non-Small Cell Lung Cancer
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.1699
https://www.valueinhealthjournal.com/article/S1098-3015(23)04829-5/fulltext
Title :
HTA14 Expanding the HTA Cost-Effectiveness Analyses for CheckMate 9LA: Nivolumab Plus Ipilimumab Plus Chemotherapy As First-Line Strategy for Non-Small Cell Lung Cancer
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)04829-5&doi=10.1016/j.jval.2023.09.1699
First page :
Section Title :
Open access? :
No
Section Order :
11145